CTLA-4 and its role in autoimmune thyroid disease

Journal of Molecular Endocrinology

Volumn 31, Issue 1, 2003, Pages 21-36

  Chistiakov, Dimitry A ^b   Turakulov, R I ^a  

^a Biology and Environment   (Australia)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

AUTOIMMUNE DISEASE; GENE LOCUS; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; NONHUMAN; PATHOGENESIS; POPULATION GENETICS; PRIORITY JOURNAL; REVIEW; THYROID DISEASE;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; GENETIC PREDISPOSITION TO DISEASE; GRAVES DISEASE; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; POLYMORPHISM, GENETIC; T-LYMPHOCYTES; THYROIDITIS, AUTOIMMUNE; VARIATION (GENETICS);

EID: 0042353836     PISSN: 09525041     EISSN: None     Source Type: Journal    
DOI: 10.1677/jme.0.0310021     Document Type: Review

References (114)

1. Akamizu T, Sale MM, Rich SS, Hiratani H, Noh JY, Kanamoto N, Sajo M, Miyamoto Y, Saito Y, Nakao K & Bowden DW 2000 Association of autoimmune thyroid disease with microsatellite markers for the thyrotropin receptor gene and CTLA-4 in Japanese patients. Thyroid 10 851-858.
2. Allahabadia A, Heward JM, Nithiyananthan R, Gibson SM, Reuser TT, Dodson PM, Franklyn JA & Gough SC 2001 MHC class II region, CTLA4 gene and opthalmopathy in patients with Graves' disease. Lancet 358 984-985.
3. Awata T, Kurihara S, Iitaka M, Takei S, Inoue I, Ishii C, Negishi K, Izumida T, Yoshida Y, Hagura R, Kuzuya N, Kanazawa Y & Katayama S 1998 Association of CTLA-4 gene A-G polymorphism (IDDM12 locus) with acute-onset and insulin-depleted IDDM as well as autoimmune thyroid disease (Graves' disease and Hashimoto's thyroiditis) in the Japanese population. Diabetes 47 128-129.
4. Badenhoop K, Donner H, Braun J, Siegmund T, Rau H & Usadel KH 1996 Genetic markers in diagnosis and prediction of relapse in Graves' disease. Experimental and Clinical Endocrinology and Diabetes. Supplement 4 104 98-100.
5. Balzano C, Buonavista N, Rouvier E & Golstein P 1992 CTLA-4 and CD28: similar proteins, neighbouring genes. International Journal of Cancer. Supplement 7 28-32.
6. Barbesino G, Tomer Y, Concepcion E, Davies TF & Greenberg DA. 1998 Linkage analysis of candidate genes in autoimmune thyroid disease: I. Selected immunoregulatory genes. International Consortium for the Genetics of Autoimmune Thyroid Disease. Journal of Clinical Endocrinology and Metabolism 83 1580-1584.
7. Barnes R, Grabs R & Polychronakos C 1997 A CTLA4 polymorphism affects lymphocyte mRNA levels but is not associated with type 1 diabetes, mellitus in Canadian dataset. Diabetologia 40 194.
8. Bartalena L, Pinchera A & Marcocci C 2000 Management of Graves' ophthalmopathy: reality and perspectives. Endocrine Reviews 21 168-199.
9. Bednarczuk T, Hiromatsu Y, Fukutani T, Jazdzewski K, Miskiewicz P, Osikowska M & Nauman J 2003 Association of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) gene polymorphism and non-genetic factors with Graves' ophthalmopathy in European and Japanese populations. European Journal of Endocrinology 148 13-18.
10. Braun J, Donner H, Siegmund T, Walfish PG, Usadel KH & Badenhoop K 1998 CTLA-4 promoter variants in patients with Graves' disease and Hashimoto's thyroiditis. Tissue Antigens 51 563-566.
11. Bugeon L, & Dallman MJ 2000 Costimulation of T cells. American Journal of Respiratory and Critical Care Medicine 162 S164-S168.
12. Buonavista N, Balzano C, Pontarotti P, Le Paslier D & Golstein P 1992 Molecular linkage of the human CTLA4 and CD28 Ig-superfamily genes in yeast artificial chromosomes. Genomics 13 856-861.
13. Buzzetti R, Nistico L, Signore A & Cascino I 1999 CTLA-4 and HLA gene susceptibility to thyroid-associated orbitopathy. Lancet 354 1824.
14. Carreno M, Bennett F, Chau TA, Ling V, Luxenberg D, Jussif J, Baroja ML & Madrenas J 2000 CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression. Journal of Immunology 165 1352-1356.
15. Cavallo MG, Leytze G & Buzzetti R 1997 Study of CTLA-4 gene expression in patients with IDDM. Diabetes 46 1319.
16. Chambers CA & Allison JP 1997 Co-stimulation in T (cell responses. Current Opinion in Immunology 9 396-404.
17. Chistiakov DA, Savost'anov KV, Turakulov RI, Petunina NA, Trukhina LV, Kudinova AV, Balabolkin MI & Nosikov VV 2000 Complex association analysis of Graves disease using a set of polymorphic markers. Molecular Genetics and Metabolism 70 214-218.
18. Cooper GS, Miller FW & Pandey JP 1999 The role of genetic factors in autoimmune disease: implications for environmental research. Environmental Health Perspectives 107 693-700.
19. Coyle AJ, Lehar S, Lloyd C, Tian A, Delaney T, Manning S, Nguyen T, Burwell T, Schneider H, Gonzalo JA, Gosselin M, Owen LR. Rudd CE & Gutierrez-Ramos JC 2000 The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity 13 95-105.
20. Dariavach P, Mattei MG, Golstein P & Lefrane MP 1988 Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains. European Journal of Immunology 18 1901-1905.
21. Deichmann K, Heinzmann A, Bruggenolte E, Forster J & Kuehr J 1996 An Mse I RFLP in the human CTLA4 promoter. Biochemical and Biophysical Research Communications 225 817-818.
22. Devendra D & Eisenbarth GS 2003 Immununologic endocrine disorders. Journal of Allergy and Clinical Immunology 111 624-636.
23. Djilali-Saiah I, Larger E, Harfouch-Hammoud E, Timsit J, Clerc J, Bertin E, Assan R, Boitard C, Bach JF & Caillat-Zuemann S 1998 No major role for the CTLA-4 gene in the association of autoimmune thyroid disease with IDDM. Diabetes 47 125-127.
24. Dong C, Juedes AE, Temann UA, Shresta S, Allison JP, Ruddle NH & Flavell RA 2001 ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 409 97-101.
25. Donner H, Braun J, Seidl C, Ran H, Finke R, Ventz M, Walfish PG. Usadel KH & Badenhoop K 1997a Codon 17 polymorphism of the cytotoxic T lymphocyte antigen 4 gene in Hashimoto's thyroiditis and Addison's disease. Journal of Clinical Endocrinology and Metabolism 82 4130-4132.
26. Donner H, Rau H, Walfish PG, Braun J, Siegmund T, Finke R, Herwig J, Usadel KH & Badenhoop K 1997b CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 82 143-146.
27. Donner H, Seidl C, Braun J, Siegmund T, Herwig J, Seifried E, Usadel KH & Badenhoop K 1998 CTLA4 gene can not protect from IDDM in the presence of high-risk HLA DQ8 or DQ2 alleles in German families. Diabetes 47 1158-1160.
28. Eguchi K 2001 Apoptosis in autoimmune diseases. Internal Medicine 40 275-284.
29. Einarsdottir E, Soderstrom I, Lofgren-Burstrom A, Haraldsson S, Nilsson-Ardnor S, Penha-Goncalves C, Lind L, Holmgren G, Holmberg M, Asplund K & Holmberg D 2003 The CTLA4 region as a general autoimmunity factor: an extended pedigree provides evidence for synergy with the HLA locus in the etiology of type 1 diabetes mellitus, Hashimoto's thyroiditis and Graves' disease. European Journal of Human Genetics 11 81-84.
30. Faber J, Wiinberg N, Schifter S & Mehlsen J 2001 Haemodynamic changes following treatment of subclinical and overt hyperthyroidism. European Journal of Endocrinology 145 391-396.
31. Farid NR & Balasz C 1998 The genetics of thyroid associated ophthalmopathy. Thyroid 1998 8 407-409.
32. Fatourechi V 2001 Subclinical thyroid disease. Mayo Clinics Proceedings 76 413-416.
33. Giorelli M, Livrea P, Defazio G, Ricchiuti F, Pagano E & Trojano M 2001 IFN-β1a modulates the expression of CTLA-4 and CD28 splice variants in human mononuclear cells: induction of soluble isoforms. Journal of Interferon and Cytokine Research 21 809-812.
34. Greene JL, Leytze GM, Emswiler J, Peach R, Bajorath J, Cosand W & Linsley PS 1996 Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. Journal of Biological Chemistry 271 26762-26771.
35. Grenet J, Teitz T, Wei T, Valentine V & Kidd VJ 1999 Structure and chromosome localization of the human CASP8 gene. Gene 226 225-232.
36. Gribben JG, Freeman GJ, Boussiotis VA, Rennert P, Jellis CA, Greenfield E, Barber M, Restivo VA Jr, Ke X, Gray SC & Nadler LM 1995 CTLA-4 mediates antigen-specific apoptosis of human T cells. PNAS 92 811-815.
37. Hadj Kaeem H, Bellassoued M, Bougacha-Elleuch N, Abid M & Ayadi H 2001 CTLA-4 gene polymorphisms in Tunisian patients with Graves' disease. Clinical Immunology 101 361-365.
38. Haimila KE, Partanen JA & Holopainen PM 2002 Genetic polymorphism of the human ICOS gene. Immunogenetics 53 1028-1032.
39. Hammond LJ, Palazzo FF, Shattock M, Goode AW & Mirakian R 2001 Thyrocyte targets and effectors of autoimmunity: a role for death receptors? Thyroid 11 919-927.
40. Harper K, Balzano C, Rouvier E, Mattei MG, Luciani MF & Golstein P 1991 CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. Journal of Immunology 147 1037-1044.
41. Heward JM, Allahabadia A, Carr-Smith J, Daykin J, Cockram CS, Gordon C, Barnett AH, Franklyn JA & Gough SC 1998 No evidence for allelic association of a human CTLA-4 promoter polymorphism with autoimmune thyroid disease in either population-based case-control or family-based studies. Clinical Endocrinology 49 331-334.
42. Heward JM, Allahabadia A, Armitage M, Hattersley A, Dodson PM, Macleod K, Carr-Smith J, Daykin J, Daly A, Sheppard MC, Holder RL, Barnett AH, Franklyn JA & Gough SC 1999 The development of Graves' disease and the CTLA-4 gene on chromosome 2q33. Journal of Clinical Endocrinology and Metabolism 84 2398-2401.
43. Huang D, Giscombe R, Zhou Y, Pirskanen R & Lefvert AK 2000 Dinucleotide repeat expansion in the CTLA-4 gene leads to T cell hyper-reactivity via the CD28 pathway in myasthenia gravis. Journal of Neuroimmunology 105 69-77.
44. Hueston WJ 2001 Treatment of hypothyroidism. American Family Physician 64 1717-1724.
45. Hunt PJ, Marshall SE, Weetman AP, Bell JI, Wass JA & Welsh KI 2000 Cytokine gene polymorphism in autoimmune thyroid disease. Journal of Clinical Endocrinology and Metabolism 85 1984-1988.
46. Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R, Anagnostopoulos I & Kroczek RA 1999 ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 397 263-266.
47. Ihara K, Ahmed S, Nakao F, Kinukawa N, Kuromaru R, Matsuura N, Iwata I, Nagafuchi S, Kohno H, Miyako K & Hara T 2001 Association studies of CTLA-4, CD28, and ICOS gene polymorphism with type 1 diabetes in the Japanese population. Immunogenetics 53 447-454.
48. Jackson CE & Puck JM 1999 Autoimmune lymphoproliferative syndrome, a disorder of apoptosis. Current Opinion in Pediatrics 11 521-527.
49. Karandikar NJ, Vanderlungt CL, Walunas TL, Miller SD & Bluestone JA 1996 CTLA-4: a negative regulator of autoimmune disease. Journal of Experimental Medicine 184 783-788.
50. Kopp P 2001 The TSH receptor and its role in thyroid disease. Cellular and Molecular Life Sciences 58 1301-1322.
51. Kotsa K, Watson PF & Weetman AP 1997 A CTLA-4 gene polymorphism is associated with both Graves' disease and autoimmune hypothyroidism. Clinical Endocrinology 46 551-554.
52. Kouki T, Sawai Y, Gardine CA, Fisfalen ME, Alegre ML & DeGroot LJ 2000 CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. Journal of Immunology 165 6606-6611.
53. Kouki T, Gardine CA, Yanagawa T & Degroot LJ 2002 Relation of three polymorphisms of the CTLA-4 gene in patients with Graves' disease. Journal of Endocrinological Investigation 25 208-213.
54. Kristiansen OP, Larsen ZM & Pociot F 2000 CTLA-4 in autoimmune diseases - a common susceptibility gene to autoimmunity? Genes and Immunity 1 170-184.
55. Lam-Tse WK, Lernmark A & Drexhage HA 2002 Animal models of endocrine/organ-specific autoimmune diseases: do they really help us to understand human autoimmunity? Springer Seminars in Immunopathology 24 297-321.
56. Larsen ZM, Kristiansen OP, Mato E, Johannesen J, Puig-Domingo M, de Leiva A, Nerup J & Pociot F 1999 IDDM12 (CTLA4) on 2q33 and IDDM13 on 2q34 in genetic susceptibility to type 1 diabetes (insulin-dependent). Autoimmunity 31 35-42.
57. Lazarus JH, Parkes AB & Premawardhana LD 2002 Postpartum thyroiditis. Autoimmunity 35 169-173.
58. Lee KM, Chuang E, Griffin M, Khattri R, Hong DK, Zhang W, Straus D, Samelson LE, Thompson CB & Bluestone JA 1998 Molecular basis of T cell inactivation by CTLA-4. Science 282 2263-2266.
59. Leung HT & Linsley PS 1994 The CD28 costimulatory pathway. Therapeutic Immunology 1 217-228.
60. Leung HT, Bradshaw J, Cleaveland JS & Linsley PS 1995 Cytotoxic T lymphocytic-associated molecule-4, a high-avidity receptor for CD80 and CD86, contains an intracellular localization motif in its cytoplasmic tail. Journal of Biological Chemistry 270 25107-25114.
61. Ligers A, Teleshova N, Masterman T, Huang WX & Hillert J 2001 CTLA-4 gene expression is influenced by promoter and exon I polymorphisms. Genes and Immunity 2 145-152.
62. Lindsten T, Lee KP, Harris ES, Petryniak B, Craighead N, Reynolds PJ. Lombard DB, Freeman GJ, Nadler LM & Gray GS 1993 Characterization of CTLA-4 structure and expression on human T cells. Journal of Immunology 151 3489-3499.
63. Ling V, Wu PW, Finnerty HF, Agostino MJ, Graham JR, Chen S, Jussiff JM, Fisk GJ, Miller CP & Collins M 2001 Assembly and annotation of human chromosome 2q33 sequence containing the CD28, CTLA4, and ICOS gene cluster: analysis by computational, comparative, and microarray approaches. Genomics 78 155-168.
64. Linsley PS, Bradshaw J, Greene J, Peach R, Bennett KL & Mittler RS 1996 Intracellular traflicking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity 4 535-543.
65. Maalej A, Bougacha N, Rebai A, Bellassouad M, Ayadi-Makni F, Abid M, Jouida J, Makni H & Ayadi H 2001 Lack of linkage and association between autoimmune thyroid diseases and the CTLA-4 gene in a large Tunisian family. Human Immunology 62 1245-1250.
66. Magistrelli G, Jeannin P, Herbault N, Benoit De Coignac A, Gauchat JF, Bonnefoy JY & Delneste Y 1999 A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. European Journal of Immunology 29 3596-3602.
67. Marron MP, Raffel LJ, Garchon HJ, Jacob CO, Serrano-Rios M, Martinez Larrad MT, Teng WP, Park Y, Zhang ZX, Goldstein DR, Tao YW, Beaurain G, Bach JF, Huang HS, Luo DF, Zeidler A, Rotter JI, Yang MC, Modilevsky T, Maclaren NK & She JX 1997 Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA-4 polymorphisms in multiple ethnic groups. Human Molecular Genetics 6 1275-1282.
68. Marron MP, Zeidler A, Raffel LJ, Eckenrode SE, Yang, JJ, Hopkins DI, Garehon HJ, Jacob CO, Serrano-Rios M, Martinez Larrad MT, Park Y, Bach JF, Rotter JI, Yang MC & She JX 2000 Genetic and physical mapping of a type 1 diabetes susceptibility gene (IDDM12) to a 100-kb phagemid artificial chromosome clone containing D2S72-CTLA4-D2S105 on chromosome 2q33. Diabetes 49 492-499.
69. Maurer M, Loserth S, Kolb-Maurer A, Ponath A, Wiese S, Kruse N & Rieckmann P 2002 A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1+49) alters T-cell activation. Immunogenetics 54 1-8.
70. Najafian N & Sayegh MH 2000 CTLA-4-Ig: a novel immunosuppressive agent. Expert Opinion on Investigational Drugs 9 2147-2157.
71. Nistico L, Buzzetti R, Pritchard LE, Van der Auwera B, Giovannini C. Bosi E, Larrad MT, Rios MS, Chow CC, Cockram CS, Jacobs K, Mijovic C, Bain SC, Barnett AH, Vandewalle CL, Schuit F, Gorus FK, Tosi R, Pozzilli P & Todd JA 1996 The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Human Molecular Genetics 5 1075-1080.
72. Nithiyananthan R, Heward JM, Allahabadia A, Franklyn JA & Gough SC 2002 Polymorphism of the CTLA-4 gene is associated Wth autoimmune hypothyroidism in the United Kingdom. Thyroid 12 3-6.
73. Oaks MK & Hallett KM 2000 Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. Journal of Immunology 164 5015-5018.
74. Oaks MK, Hallett KM, Penwell RT, Stauber EC, Warren SJ & Tector AJ 2000 A native soluble form of CTLA-4. Cellular Immunology 201 144-153.
75. Ohashi J, Yamamoto S, Tsuchiya N, Hatta Y, Komata T, Matsushita M & Tokunaga K 2001 Comparison of statistical power between 2 × 2 allele frequency and positivity tables in case control studies of complex disease genes. Annals of Human Genetics 65 197-206.
76. Oosterwegel MA, Greenwald RJ, Mandelbrot DA, Lorsbach RB & Sharpe AH 1999 CTLA-4 and T cell activation. Current Opinion in Immunology 11 294-300.
77. Park YJ, Chung HK, Park DJ, Kim WB, Kim SW, Koh JJ & Cho BY 2000 Polymorphism in the promoter and exon 1 of the cytotoxic T lymphocyte antigen-4 gene associated with autoimmune thyroid disease in Koreans. Thyroid 10 453-459.
78. Perez VL, Van Parijs L, Biuckians A, Zheng XX, Strom TB & Abbas AK 1997 Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 6 411-417.
79. Petrone A, Giorgi G, Mesturino CA, Capizzi M, Cascino I, Nistico L, Osborn J, Di Mario U & Buzzetti R 2001 Association of DRB1*04-DQB1*0301 haplotype and lack Of association of two polymorphic sites at CTLA-4 gene with Hashimoto's thyroiditis in an Italian population. Thyroid 11 171-175.
80. Polymeropoulos MH, Xiao H, Rath DS & Merril CR 1991 Dinucleotide repeat polymorphism at the human CTLA4 gene. Nucleic Acids Research 19 4018.
81. Rapoport B & McLachlan SM 2001 Thyroid autoimmunity. Journal of Clinical Investigation 108 1253-1259.
82. Riley JL, Blair PJ, Musser JT, Abe R, Tezuka K, Tsuji T & June CH 2001 ICOS costimulation requires IL-2 and can be prevented by CTLA-4 engagement. Journal of Immunology 166 4943-4948
83. Sakai K, Shirasawa S, Ishikawa N, Ito K, Tamai H, Kuma K, Akamizu T, Tanimura M, Furugaki K, Yamamoto K & Sasazuki T 2001 Identification of susceptibility loci for autoimmune thyroid disease to 5q31-q33 and Hashimoto's thyroiditis to 8q23-q24 by multipoint affected sib-pair linkage analysis in Japanese. Human Molecular Genetics 10 1379-1386.
84. Sale MM, Akamizu T, Howard TD, Yokota T, Nakao K, Mori T, Iwasaki H, Rich SS, Jennings-Gee JE, Yamada M & Bowden DW 1997 Association of autoimmune thyroid disease with a microsatellite, marker for the thyrotropin receptor gene and CTLA-4 in a Japanese population. Proceedings of the Association of American Physicians 109 453-461.
85. Shaw G & Kamen R 1986 A conserved AU sequence front the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 46 659-667.
86. She JX & Marron MP 1998 Genetic susceptibility factors in type 1 diabetes: linkage, disequilibrium and functional analyses. Current Opinion in Immunology 10 682-689.
87. Shimojo N, Kohno Y, Yamaguchi K, Kikuoka S, Hoshioka A, Niiimi H, Hirai A, Tamura Y, Saito Y, Kohn LD & Tahara K 1996 Induction of Graves-like disease in mice by immunization with fibroblasts transfected with the thyrotropin receptor and a class II molecule. PNAS 93 11074-11079.
88. Simon SM & Blobel G 1991 A protein-conducting channel in the endoplasmic reticulum. Cell 65 371-380.
89. Sprick MR, Rieser E, Stahl H, Grosse-Wilde A, Weigand MA & Walczak H 2002 Caspase-10 is restricted to and activated at the native TRAIL and CD95 death-inducing signalling complexes in FADD-dependent manner but can not functionally substitute caspase-8. EMBO Journal 21 4520-4530.
90. Stagnaro-Green A 2000 Recognizing, understanding, and treating postpartum thyroiditis. Endocrinology and Metabolism Clinics of North America 29 417-430.
91. Stassi G & De Maria R 2002 Autoimmune thyroid disease: new models of cell death in autoimmunity. Nature Reviews. Immunology 2 195-204.
92. Stassi G, Di Liberto D, Todaro M, Zeuner A, Ricci-Vitiani L, Stoppacciaro A, Ruco L, Farina F, Zummo G & De Maria R 2000 Control of target cell survival in thyroid autoimmunity by T helper cytokines via regulation of apoptotic proteins. Nature Immunology 1 483-488.
93. Tivol EA. Borriello F, Schweitzer AN, Lynch WP, Bluestone JA & Sharpe AH 1995 Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3 541-547.
94. Tivol EA, Schweitzer AN & Sharpe AH 1996 Costimulation and autommunity. Current Opinion in Immunology 8 822-830.
95. Tomer Y 2001 Unraveling the genetic susceptibility to autoimmune thyroid disease: CTLA-4 takes the stage. Thyroid 11 167-169.
96. Tomer Y & Davies TF 1997 The genetic susceptibility to Graves' disease. Bailliere's Clinical Endocrinology and Metabolism 1997 11 431-450.
97. Tomer Y, Barbesino G, Greenberg DA, Concepcion E & Davies TF 1999 Mapping the major susceptibility loci for familial Graves' and Hashimoto's diseases: evidence for genetic heterogencity and gene interactions. Journal of Clinical Endocrinology and Metabolism 84 4656-4664.
98. Tomer Y, Greenberg DA, Barbesino G, Concepcion E & Davies TF 2001 CTLA-4 and not CD28 is a susceptibility gene for thyroid autoantibody production. Journal of Clinical Endocrinology and Metabolism 86 168-1693.
99. Tomoyose T, Komiya I, Takara M, Yabiku K, Kinjo Y, Shimajiri Y, Yogi H, Kouki T, Masuda M & Takasu N 2002 Cytotoxic T-lymphocyte antigen-4 gene polymorphisms and human T-cell lymphotrophic virus-1 infection: their associations with Hashimoto's thyroiditis in Japanese patients. Thyroid 12 673-677.
100. Tsuchiya N, Ohashi J & Tokunaga K 2002 Variation in immune response genes and their associations with multifactorial immune disorders. Immunological 190 169-181.
101. Vaidya B, Imrie H, Perros P, Dickinson J, McCarthy MI, Kendall-Taylor P & Pearce SH 1999a Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism confers susceptibility to thyroid associated orbitopathy. Lancet 354 743-744.
102. Vaidya B, Imrie H, Perros P, Young ET, Kelly WF, Carr D, Large DM, Toft AD, McCarthy MI, Kendall-Taylor P & Pearce SH 1999b The cytotoxic T lymphocyte antigen-4 is a major Graves' disease locus. Human Molecular Genetics 8 1195-1199.
103. Villanueva R, Inzerillo AM, Tomer Y, Barbesino G, Melter M, Concepcion ES, Greenberg DA, MacLaren N, Sun ZS, Zhang DM, Tucci S & Davies TF 2000 Limited genetic susceptibility to severe Graves' ophthalmopathy: no role for CTL4-4 but evidence for an environmental etiology. Thyroid 10 791-798.
104. Villanueva R, Tomer Y, Greenberg DA, Mao C, Concepcion ES, Tucci S, Estilo G & Davies TF 2002 Autoimmune thyroid disease susceptibility loci in a large Chinese family. Clinical Endocrinology 56 45-51.
105. Wang C & Crapo LM 1997 The epidemiology of thyroid disease and implications for screening. Endocrinology and Metabolism Clinics of North America 26 189-218.
106. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H & Mak TW 1995 Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270 985-988.
107. Waterman EA, Watson PF, Lazarus JH, Parkes AB, Darke C & Weetman AP 1998 A study of the association between a polymorphism in the CTLA-4 gene and postpartum thyroiditis. Clinical Endocrinology 49 251-255.
108. Weetman AP 2003 Autoimmune thyroid disease: propagation and progression. European Journal of Endocrinology 148 1-9.
109. Wiersinga WM & Bartalena L 2002 Epidemiology and prevention of Graves' ophthalmopathy. Thyroid 12 855-860.
110. Xu Y, Graves PN, Tomer Y & Davies TF2002 CTL-4 and autoimmune thyroid disease: lack of influence of the A49 G signal peptide polymorphism on functional recombinant human CTLA-4. Cellular Immunology 215 133-140.
111. Yanagawa T, Hidaka Y, Guimaraes V, Soliman M & DeGroot LJ 1995 CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population. Journal of Clinical endocrinology and Melabolism 80 41-45.
112. Yanagawa T, Taniyama M, Enomoto S, Gomi K, Maruyama H, Ban Y & Saruta T 1997 CTLA4 gene polymorphism confers susceptibility to Graves' disease in Japanese. Thyroid 7 843-846.
113. Yung E, Cheng PS, Fok TF & Wong GW 2002 CTLA-4 gene A-G polymorphism and childhood Graves' disease. Clinical Endocrinology 56 649-653.
114. Zaletel K, Krhin B, Gaberscek S, Pirnat E & Hojker S 2002 The Influence of the exon 1 polymorphism of the cytotoxic T lymphocyte antigen 4 gene on thyroid antibody production in patients with newly diagnosed Graves' disease. Thyroid 12 373-376.